Bausch Health Companies Inc. (NYSE:BHC) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET

Company Participants

Christina Cheng - Senior Vice President, Investor Relations

Thomas Appio - Chief Executive Officer

Tom Vadaketh - Chief Financial Officer

Conference Call Participants

Ken Cacciatore - Cowen & Company

Annabel Samimy - Stifel

Gary Nachman - BMO

Greg Fraser - Truist Securities

Umer Raffat - Evercore

Sahil Dhingra - RBC

Operator

Good morning and welcome to the Bausch Health Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Christina Cheng, Senior Vice President, Investor Relations. Please go ahead.

Christina Cheng

Thanks, Andrew. Good morning and welcome to our second quarter 2022 earnings conference call. Participating in today’s call are Thomas J. Appio, Chief Executive Officer of Bausch Health and Tom Vadaketh, Chief Financial Officer of Bausch Health.

Before we begin, I’d like to remind you that our presentation today contains forward-looking information. We would like to ask you to take a moment to read the forward-looking statements at the beginning of the slides that accompany this presentation. They contain important information. Our actual results may vary materially from these expressed or implied in our forward-looking statements and you should not place undue reliance on any forward-looking statements.

Please refer to our SEC filings and filings with the Canadian securities administrators for a list of some of the factors that could cause our actual results to differ materially from our expectations. We use non-GAAP financial measures to help investors understand our ongoing business performance. Non-GAAP financial measures may not be comparable to similarly titled measures used by other companies and should be considered along with, but not as an alternative to, operating performance measures calculated in accordance to GAAP. You will find reconciliations to our non-GAAP measures in the appendix of the slides that accompany this presentation available in Bausch Health’s Investor Relations website.

Finally, the financial guidance in this presentation is effective as of today only. We do not undertake any obligation to update guidance. Our discussion today will focus on Bausch Pharma and Solta. However, we will briefly comment on B&L’s results. Beginning this quarter, when discussing consolidated Bausch Health Companies Inc. results, we will include a discussion of results attributable to Bausch Health Companies, Inc., which excludes a portion of Bausch & Lomb’s results attributable to the approximately 11.3% ownership interest in Bausch & Lomb, not owned by Bausch Health. Please refer to Bausch & Lomb separate 10-Q and earnings release last week for more details on Bausch & Lomb’s results.